232 related articles for article (PubMed ID: 31436048)
21. The inhibin/activin signalling pathway in human gonadal and adrenal cancers.
Marino FE; Risbridger G; Gold E
Mol Hum Reprod; 2014 Dec; 20(12):1223-37. PubMed ID: 25180271
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle.
Hardee JP; Counts BR; Gao S; VanderVeen BN; Fix DK; Koh HJ; Carson JA
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):369-383. PubMed ID: 29215198
[TBL] [Abstract][Full Text] [Related]
23. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
Coerver KA; Woodruff TK; Finegold MJ; Mather J; Bradley A; Matzuk MM
Mol Endocrinol; 1996 May; 10(5):534-43. PubMed ID: 8732684
[TBL] [Abstract][Full Text] [Related]
24. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.
Kandarian SC; Nosacka RL; Delitto AE; Judge AR; Judge SM; Ganey JD; Moreira JD; Jackman RW
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1109-1120. PubMed ID: 30270531
[TBL] [Abstract][Full Text] [Related]
25. Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours.
Negri DR; Mezzanzanica D; Sacco S; Gadina M; Benigni F; Cajola L; Finocchiaro G; Ghezzi P; Canevari S
Cytokine; 2001 Jul; 15(1):27-38. PubMed ID: 11509006
[TBL] [Abstract][Full Text] [Related]
26. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
[TBL] [Abstract][Full Text] [Related]
27. Paracrine Activin-A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion.
Donovan P; Dubey OA; Kallioinen S; Rogers KW; Muehlethaler K; Müller P; Rimoldi D; Constam DB
J Invest Dermatol; 2017 Dec; 137(12):2578-2587. PubMed ID: 28844941
[TBL] [Abstract][Full Text] [Related]
28. Pluripotency gene expression and growth control in cultures of peripheral blood monocytes during their conversion into programmable cells of monocytic origin (PCMO): evidence for a regulatory role of autocrine activin and TGF-β.
Ungefroren H; Hyder A; Hinz H; Groth S; Lange H; El-Sayed KM; Ehnert S; Nüssler AK; Fändrich F; Gieseler F
PLoS One; 2015; 10(2):e0118097. PubMed ID: 25707005
[TBL] [Abstract][Full Text] [Related]
29. OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling.
Song F; Chen Q; Rao W; Zhang R; Wang Y; Ge H; Wei Q
EBioMedicine; 2019 Mar; 41():156-166. PubMed ID: 30833190
[TBL] [Abstract][Full Text] [Related]
30. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic potential of blocking the activin signalling pathway.
Marino FE; Risbridger G; Gold E
Cytokine Growth Factor Rev; 2013 Oct; 24(5):477-84. PubMed ID: 23787160
[TBL] [Abstract][Full Text] [Related]
32. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Di Simone N; Crowley WF; Wang QF; Sluss PM; Schneyer AL
Endocrinology; 1996 Feb; 137(2):486-94. PubMed ID: 8593793
[TBL] [Abstract][Full Text] [Related]
33. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.
Hetzler KL; Hardee JP; Puppa MJ; Narsale AA; Sato S; Davis JM; Carson JA
Biochim Biophys Acta; 2015 May; 1852(5):816-25. PubMed ID: 25555992
[TBL] [Abstract][Full Text] [Related]
34. Tumour-derived transforming growth factor-β signalling contributes to fibrosis in patients with cancer cachexia.
Lima JDCC; Simoes E; de Castro G; Morais MRPT; de Matos-Neto EM; Alves MJ; Pinto NI; Figueredo RG; Zorn TMT; Felipe-Silva AS; Tokeshi F; Otoch JP; Alcantara P; Cabral FJ; Ferro ES; Laviano A; Seelaender M
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1045-1059. PubMed ID: 31273954
[TBL] [Abstract][Full Text] [Related]
35. R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.
Chrysostomou SE; Eder S; Pototschnig I; Mayer AL; Derler M; Mussbacher M; Schauer S; Zhang D; Yan D; Liu G; Hoefler G; Weichhart T; Vesely PW; Zhang L; Schweiger M
J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):562-574. PubMed ID: 38302863
[TBL] [Abstract][Full Text] [Related]
36. Effect of cytokines and growth factors on the secretion of inhibin A, activin A and follistatin by term placental villous trophoblasts in culture.
Mohan A; Asselin J; Sargent IL; Groome NP; Muttukrishna S
Eur J Endocrinol; 2001 Oct; 145(4):505-11. PubMed ID: 11581011
[TBL] [Abstract][Full Text] [Related]
37. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
Cipriano SC; Chen L; Kumar TR; Matzuk MM
Endocrinology; 2000 Jul; 141(7):2319-27. PubMed ID: 10875231
[TBL] [Abstract][Full Text] [Related]
38. Role of interleukin-6 in cachexia: therapeutic implications.
Narsale AA; Carson JA
Curr Opin Support Palliat Care; 2014 Dec; 8(4):321-7. PubMed ID: 25319274
[TBL] [Abstract][Full Text] [Related]
39. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment.
Ren C; Cheng X; Lu B; Yang G
Eur J Cancer; 2013 Dec; 49(18):3889-99. PubMed ID: 23953057
[TBL] [Abstract][Full Text] [Related]
40. Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent.
Reddel CJ; Allen JD; Ehteda A; Taylor R; Chen VM; Curnow JL; Kritharides L; Robertson G
J Thromb Haemost; 2017 Mar; 15(3):477-486. PubMed ID: 28058802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
